Incidence and risk factors of trastuzumab-induced cardiac dysfunction in a predominantly Hispanic South Texas population: a descriptive study

Abstract Background Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2), is often the first line treatment for HER2 positive breast cancer. Although trastuzumab is effective, it has cardiotoxic effects and therefore requires cardiotoxicity monitoring via serial...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Aditi Sharma, Maria E. Fierro, Samuel Governor, Aishwarya Kothare, Stella Pak, Karen Liu, Zuha Alam, Prince Otchere
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2025-02-01
Schriftenreihe:	Cardio-Oncology
Schlagworte:	Trastuzumab Cardiotoxicity Cardio-oncology Health disparities Breast cancer
Online-Zugang:	https://doi.org/10.1186/s40959-025-00319-4
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!